Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model

Toxicology

Volumn 331, Issue , 2015, Pages 47-56

  Komulainen, Tuomas ^a,b   Lodge, Tiffany ^c   Hinttala, Reetta ^a,b   Bolszak, Maija ^a,b   Pietilä, Mika ^d   Koivunen, Peppi ^e   Hakkola, Jukka ^a,e   Poulton, Joanna ^c   Morten, Karl J ^c   Uusimaa, Johanna ^a,b  

^a MEDICAL RESEARCH CENTER OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OULU   (Finland)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

Hepatotoxicity; HepG2; Mitochondrial respiration; Mitochondrial toxicity; Reactive oxygen species; Sodium valproate

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIHYDROLIPOAMIDE DEHYDROGENASE; GALACTOSE; GLUCOSE; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL DNA; OXOGLUTARATE DEHYDROGENASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; VALPROIC ACID; ANTICONVULSIVE AGENT; MULTIENZYME COMPLEX; SUPEROXIDE DISMUTASE;

ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL RESPIRATION; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RESPIRATORY CHAIN; CHEMICALLY INDUCED; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; HEPG2 CELL LINE; LIVER CELL; LIVER MITOCHONDRION; METABOLISM; PATHOLOGY; TIME;

ADENOSINE TRIPHOSPHATE; ANTICONVULSANTS; CELL DEATH; CELL PROLIFERATION; CELL RESPIRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; GALACTOSE; GLUCOSE; HEP G2 CELLS; HEPATOCYTES; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, LIVER; MITOCHONDRIAL DISEASES; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PYRUVIC ACID; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TIME FACTORS; VALPROIC ACID;

EID: 84925233499     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2015.03.001     Document Type: Article

References (49)

1. Aires C.C., Ijlst L., Stet F., Prip-Buus C., de Almeida I.T., Duran M., Wanders R.J., Silva M.F. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem. Pharmacol. 2010, 79:792-799.
2. Begriche K., Massart J., Robin M.A., Borgne-Sanchez A., Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol. 2011, 54:773-794.
3. Benavides J., Martin A., Ugarte M., Valdivieso F. Inhibition by valproic acid of pyruvate uptake by brain mitochondria. Biochem. Pharmacol. 1982, 31:1633-1636.
4. Boelsterli U.A., Lim P.L. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity?. Toxicol. Appl. Pharmacol. 2007, 220:92-107.
5. Bryant A.E., Dreifuss F.E. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996, 46:465-469.
6. Buckman J.F., Hernandez H., Kress G.J., Votyakova T.V., Pal S., Reynolds I.J. MitoTracker labeling in primary neuronal and astrocytic cultures: influence of mitochondrial membrane potential and oxidants. J. Neurosci. Methods 2001, 104:165-176.
7. Callaghan N., Kenny R.A., O'Neill B., Crowley M., Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J. Neurol. Neurosurg. Psychiatry 1985, 48:639-644.
8. Chan S.S., Copeland W.C. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. Biochim. Biophys. Acta 2009, 1787:312-319.
9. Clavijo-Cornejo D., Gutierrez-Carrera M., Palestino-Dominguez M., Dominguez-Perez M., Nuno N., Souza V., Miranda R.U., Kershenobich D., Gutierrez-Ruiz M.C., Bucio L., Gomez-Quiroz L.E. Acetaldehyde targets superoxide dismutase 2 in liver cancer cells inducing transient enzyme impairment and a rapid transcriptional recovery. Food Chem. Toxicol. 2014, 69:102-108.
10. Cotariu D., Zaidman J.L. Valproic acid and the liver. Clin. Chem. 1988, 34:890-897.
11. Cowell R.M., Talati P., Blake K.R., Meador-Woodruff J.H., Russell J.W. Identification of novel targets for PGC-1alpha and histone deacetylase inhibitors in neuroblastoma cells. Biochem. Biophys. Res. Commun. 2009, 379:578-582.
12. Delarue A., Paut O., Guys J.M., Montfort M.F., Lethel V., Roquelaure B., Pellissier J.F., Sarles J., Camboulives J. Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure. Pediatr. Transplant. 2000, 4:67-71.
13. Graziewicz M.A., Longley M.J., Copeland W.C. DNA polymerase gamma in mitochondrial DNA replication and repair. Chem. Rev. 2006, 106:383-405.
14. Haas R., Stumpf D.A., Parks J.K., Eguren L. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 1981, 31:1473-1476.
15. Helbling D., Buchaklian A., Wang J., Wong L.J., Dimmock D. Reduced mitochondrial DNA content and heterozygous nuclear gene mutations in patients with acute liver failure. J. Pediatr. Gastroenterol. Nutr. 2013, 57:438-443.
16. Jonckheere A.I., Huigsloot M., Janssen A.J., Kappen A.J., Smeitink J.A., Rodenburg R.J. High-throughput assay to measure oxygen consumption in digitonin-permeabilized cells of patients with mitochondrial disorders. Clin. Chem. 2010, 56:424-431.
17. Kaguni L.S. DNA polymerase gamma: the mitochondrial replicase. Annu. Rev. Biochem. 2004, 73:293-320.
18. Kiang T.K., Teng X.W., Karagiozov S., Surendradoss J., Chang T.K., Abbott F.S. Role of oxidative metabolism in the effect of valproic acid on markers of cell viability necrosis, and oxidative stress in sandwich-cultured rat hepatocytes. Toxicol. Sci. 2010, 118:501-509.
19. Koenig S.A., Buesing D., Longin E., Oehring R., Haussermann P., Kluger G., Lindmayer F., Hanusch R., Degen I., Kuhn H., Samii K., Jungck A., Bruckner R., Seitz R., Boxtermann W., Weber Y., Knapp R., Richard H.H., Weidner B., Kasper J.M., Haensch C.A., Fitzek S., Hartmann M., Borusiak P., Muller-Deile A., Degenhardt V., Korenke G.C., Hoppen T., Specht U., Gerstner T. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006, 47:2027-2031.
20. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003, 349:474-485.
21. Li S., Guo J., Ying Z., Chen S., Yang L., Chen K., Long Q., Qin D., Pei D., Liu X. Valproic-acid induced hepatotoxicity in Alpers syndrome is associated with mPTP opening dependent apoptotic sensitivity in an iPSC model. Hepatology 2015, 10.1002/hep.27712.
22. Luis P.B., Ruiter J.P., Aires C.C., Soveral G., de Almeida I.T., Duran M., Wanders R.J., Silva M.F. Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation. Biochim. Biophys. Acta 2007, 1767:1126-1133.
23. Marroquin L.D., Hynes J., Dykens J.A., Jamieson J.D., Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 2007, 97:539-547.
24. McFarland R., Hudson G., Taylor R.W., Green S.H., Hodges S., McKiernan P.J., Chinnery P.F., Ramesh V. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). BMJ Case Rep. 2009, 10.1136/bcr.12.2008.1303.
25. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
26. Ong M.M., Wang A.S., Leow K.Y., Khoo Y.M., Boelsterli U.A. Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice. Free Radical Biol. Med. 2006, 40:420-429.
27. Osellame L.D., Blacker T.S., Duchen M.R. Cellular and molecular mechanisms of mitochondrial function. Best Pract. Res. Clin. Endocrinol. Metab. 2012, 26:711-723.
28. Palmfeldt J., Vang S., Stenbroen V., Pedersen C.B., Christensen J.H., Bross P., Gregersen N. Mitochondrial proteomics on human fibroblasts for identification of metabolic imbalance and cellular stress. Proteome Sci. 2009, 7. 10.1186/1477-5956-7-20.
29. Pendergrass W., Wolf N., Poot M. Efficacy of MitoTracker Green and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues. Cytometry 2004, 61:162-169.
30. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16:695-714.
31. Pessayre D., Mansouri A., Haouzi D., Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 1999, 15:367-373.
32. Pinti M., Troiano L., Nasi M., Ferraresi R., Dobrucki J., Cossarizza A. Hepatoma HepG2 cells as a model for in vitro studies on mitochondrial toxicity of antiviral drugs: which correlation with the patient?. J. Biol. Regul. Homeost. Agents 2003, 17:166-171.
33. Ponchaut S., van Hoof F., Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA AT to the observed inhibitions. Biochem. Pharmacol. 1992, 43:2435-2442.
34. Pourahmad J., Eskandari M.R., Kaghazi A., Shaki F., Shahraki J., Fard J.K. A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis. Toxicol. In Vitro 2012, 26:545-551.
35. Saneto R.P., Lee I.C., Koenig M.K., Bao X., Weng S.W., Naviaux R.K., Wong L.J. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010, 19:140-146.
36. Saruwatari J., Deguchi M., Yoshimori Y., Noai M., Yoshida S., Ogusu N., Oniki K., Yoshida S., Yasui-Furukori N., Kaneko S., Ishitsu T., Nakagawa K. Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases. Epilepsy Res. 2012, 99:183-186.
37. Scheffner D., Konig S., Rauterberg-Ruland I., Kochen W., Hofmann W.J., Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988, 29:530-542.
38. Schmid M.M., Freudenmann R.W., Keller F., Connemann B.J., Hiemke C., Gahr M., Kratzer W., Fuchs M., Schonfeldt-Lecuona C. Non-fatal and fatal liver failure associated with valproic acid. Pharmacopsychiatry 2013, 46:63-68.
39. Schwabe M.J., Dobyns W.B., Burke B., Armstrong D.L. Valproate-induced liver failure in one of two siblings with Alpers disease. Pediatr. Neurol. 1997, 16:337-343.
40. Silva M.F., Aires C.C., Luis P.B., Ruiter J.P., IJlst L., Duran M., Wanders R.J., Tavares de Almeida I. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J. Inherit. Metab. Dis. 2008, 31:205-216.
41. Silva M.F., Ruiter J.P., Illst L., Jakobs C., Duran M., de Almeida I.T., Wanders R.J. Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro. J. Inherit. Metab. Dis. 1997, 20:397-400.
42. Sitarz K.S., Elliott H.R., Karaman B.S., Relton C., Chinnery P.F., Horvath R. Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts. Mol. Genet. Metab. 2014, 112:57-63.
43. Stewart J.D., Horvath R., Baruffini E., Ferrero I., Bulst S., Watkins P.B., Fontana R.J., Day C.P., Chinnery P.F. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010, 52:1791-1796.
44. Surendradoss J., Chang T.K., Abbott F.S. Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 2012, 264:413-422.
45. Tong V., Teng X.W., Chang T.K., Abbott F.S. Valproic acid I: time course of lipid peroxidation biomarkers liver toxicity, and valproic acid metabolite levels in rats. Toxicol. Sci. 2005, 86:427-435.
46. Tong V., Teng X.W., Chang T.K., Abbott F.S. Valproic acid II: effects on oxidative stress mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol. Sci. 2005, 86:436-443.
47. Wang W., Liao X.L., Chen J.H., Li D.D., Lin C.L., Yan Y.X., Tang Y.H., Jiang J.W. Sodium valproate induces mitochondria-dependent apoptosis in human hepatoblastoma cells. Chin. Med. J. (Engl.) 2011, 124:2167-2172.
48. Webster K.A. Mitochondrial membrane permeabilization and cell death during myocardial infarction: roles of calcium and reactive oxygen species. Future Cardiol. 2012, 8:863-884.
49. Westerink W.M., Schoonen W.G. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 2007, 21:1581-1591.